Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. Issue 4 (July 2018)

• Record Type: Journal Article
• Authors: Bertoletti, Laurent; Benhamou, Ygal; Béjot, Yannick; Marechaux, Sylvestre; Cheggour, Saida; Aleil, Boris; Lellouche, Nicolas; Dillinger, Jean-Guillaume; Delluc, Aurélien
• Is Part Of: Blood reviews. Volume 32:Issue 4(2018:Jul.)
• Page Start: 272
• Page End: 279
• Publication Date: 2018-07
• Subjects: Direct oral anticoagulants -- Cerebral venous thrombosis -- Splanchnic venous thrombosis -- Inherited thrombophilia -- Antiphospholipid syndrome; Hematology -- Periodicals; Hematology -- Periodicals; Hématologie -- Périodiques; Hematology; Electronic journals; Periodicals; 616.15
• DOI: 10.1016/j.blre.2018.01.002
• Languages: English
• ISSNs: 0268-960X

Abstract

Abstract: Direct oral anticoagulants (DOACs) are indicated in the treatment and prevention of venous thromboembolism (VTE). However, the use of DOACs in unusual VTE, including cerebral venous thrombosis (CVT) and splanchnic venous thrombosis (SVT), and in patients with biological thrombophilia including minor thrombophilia (Factor V Leiden and prothrombin G20210A), major innate thrombophilia (protein C and S deficiency, and antithrombin) and major acquired thrombophilia (antiphospholipid syndrome [APS]), remains controversial due to the paucity of available data. There are some reports of DOACs use in the initial treatment or long-term maintenance of patients with either CVT or SVT, but their efficacy remains unclear. The efficacy of DOACs may be suitable in patients with biological minor or major thrombophilia. The use of DOACs for the long-term maintenance of patients with APS is more contentious. Randomized clinical trials, which are currently underway, should offer definitive insight into the efficacy and safety profiles of DOACs in these patient populations.